Purpose: Renal cell carcinoma (RCC) forming tumor thrombus (TT) of vena cava (VC) is characterized by poor prognosis. Nevertheless, the outcome of patients after radical surgery varies. To date only limited data concerning prognostic biomarkers in this RCC subgroup are available. Methods: Out of 159 patients with pT3b/c RCC, 95 patients without synchronous distant metastases at time of diagnosis were included in the study cohort. After immunohistochemical (IHC) evaluation of E-cadherin and β-Catenin expression, association with clinical, histopathological and survival was assessed by univariate analysis, multivariate analysis, and Kaplan-Meier-analysis. Cancer-specific survival (CSS) rates and overall survival (OS) rates were estimated using Kaplan-Meier analysis and compared using Log rank test. Results: We found a significant correlation between E-cadherin overexpression and initial lymph node metastasis (ρ = 0.300, p = 0.003), positive surgical margins (ρ = 0.210, p = 0.043), and the development of distant metastases (ρ = 0.258, p = 0.012). Furthermore, we observed a significant correlation of β-Catenin overexpression with higher tumor stage pT3c (ρ = 0.230, p = 0.028) and initial lymph node metastases (ρ = 0.236, p = 0.025). Survival analysis revealed a statistically significant association of both E-cadherin and β-Catenin overexpression with worse CSS (p < 0.001 and p = 0.007, respectively) and OS (p < 0.001 and p = 0.041, respectively). Multivariate analysis revealed initial lymph node metastasis as the only predictive factor for worse OS (HR 4.54, 95% CI 2.30–8.93; p < 0.001). E-Cadherin and β-Catenin expression failed to be significant in multivariable analysis for OS and CSS. Conclusions: In a large series of RCC with TT of VC high IHC expression of E-cadherin and β-Catenin was associated with initial lymph node metastasis and with both worse OS and worse CSS. This might help to identify patients at risk for recurrence who might benefit from adjuvant therapy or stricter follow-up.

Keywords:
Renal cell carcinoma, Vena cava infiltration, Tumor thrombus, E-cadherin, β-Catenin
1.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.
Eur J Cancer
. 2013 Apr; 49(6): 1374–403.
2.
Patard JJ, Rodriguez A, Rioux-Leclercq N, Guillé F, Lobel B. Prognostic significance of the mode of detection in renal tumours.
BJU Int
. 2002 Sep; 90(4): 358–63.
3.
Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors.
J Urol
. 2000 Feb; 163(2): 426–30.
4.
Kato M, Suzuki T, Suzuki Y, Terasawa Y, Sasano H, Arai Y. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis.
J Urol
. 2004 Sep; 172(3): 863–6.
5.
Lawindy SM, Kurian T, Kim T, Mangar D, Armstrong PA, Alsina AE, et al. Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus.
BJU Int
. 2012 Oct; 110(7): 926–39.
6.
Karnes RJ, Blute ML. Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus.
Nat Clin Pract Urol
. 2008 Jun; 5(6): 329–39.
7.
García-Fadrique G, Budía-Alba A, Ruiz-Cerdá JL, Morales-Solchaga G, Pontones JL, Jiménez-Cruz JF. [Prognostic value of -venous tumor thrombus in renal cell carcinoma].
Actas Urol Esp
. 2012 Jan; 36(1): 29–34.
8.
Morgan TM, Tang D, Stratton KL, Barocas DA, Anderson CB, Gregg JR, et al. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma.
Eur Urol
. 2011 Jun; 59(6): 923–8.
9.
Lund L, Jacobsen J, Nørgaard M, McLaughlin JK, Blot WJ, Borre M, et al. The prognostic impact of comorbidities on renal cancer, 1995 to 2006: a Danish population based study.
J Urol
. 2009 Jul; 182(1): 35–40.
10.
Pouliot F, Shuch B, Larochelle JC, Pantuck A, Belldegrun AS. Contemporary management of renal tumors with venous tumor thrombus.
J Urol
. 2010 Sep; 184(3): 833–41.
11.
Whitson JM, Reese AC, Meng MV. Population based analysis of survival in patients with renal cell carcinoma and venous tumor thrombus.
Urol Oncol
. 2013 Feb; 31(2): 259–63.
12.
Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review.
Eur Urol
. 2011 Oct; 60(4): 644–61.
13.
Vergho DC, Kneitz S, Kalogirou C, Burger M, Krebs M, Rosenwald A, et al. Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava.
PLoS One
. 2014 Oct; 9(10):e109877.
14.
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition.
J Clin Invest
. 2009 Jun; 119(6): 1420–8.
15.
Zhang X, Yang M, Shi H, Hu J, Wang Y, Sun Z, et al. Reduced E-cadherin facilitates renal cell carcinoma progression by WNT/β-catenin signaling activation.
Oncotarget
. 2017 Mar; 8(12): 19566–76.
16.
Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, et al. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
BJU Int
. 2016 Feb; 117(2): 351–62.
17.
Katagiri A, Watanabe R, Tomita Y. E-cadherin expression in renal cell cancer and its significance in metastasis and survival.
Br J Cancer
. 1995 Feb; 71(2): 376–9.
18.
Krabbe LM, Westerman ME, Bagrodia A, Gayed BA, Darwish OM, Haddad AQ, et al. Dysregulation of β-catenin is an independent predictor of oncologic outcomes in patients with clear cell renal cell carcinoma.
J Urol
. 2014 Jun; 191(6): 1671–7.
19.
Yang CM, Ji S, Li Y, Fu LY, Jiang T, Meng FD. β-Catenin promotes cell proliferation, migration, and invasion but induces apoptosis in renal cell carcinoma.
OncoTargets Ther
. 2017 Feb; 10: 711–24.
20.
Kim H, Rodriguez-Navas C, Kollipara RK, Kapur P, Pedrosa I, Brugarolas J, et al. Unsaturated Fatty Acids Stimulate Tumor Growth through Stabilization of β-Catenin.
Cell Reports
. 2015 Oct; 13(3): 495–503.
21.
Kruck S, Eyrich C, Scharpf M, Sievert KD, Fend F, Stenzl A, et al. Impact of an altered Wnt1/β-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma.
Int J Mol Sci
. 2013 May; 14(6): 10944–57.
22.
Kovacs G, Billfeldt NK, Farkas N, Dergez T, Javorhazy A, Banyai D, et al. Cytoplasmic expression of β-catenin is an independent predictor of progression of conventional renal cell carcinoma: a simple immunostaining score.
Histopathology
. 2017 Jan; 70(2): 273–80.
23.
Klatte T, Pantuck AJ, Riggs SB, Kleid MD, Shuch B, Zomorodian N, et al. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
J Urol
. 2007 Oct; 178(4 Pt 1): 1189–95.
24.
Ciancio G, Manoharan M, Katkoori D, De Los Santos R, Soloway MS. Long-term survival in patients undergoing radical nephrectomy and inferior vena cava thrombectomy: single-center experience.
Eur Urol
. 2010 Apr; 57(4): 667–72.
25.
Tilki D, Nguyen HG, Dall’Era MA, Bertini R, Carballido JA, Chromecki T, et al. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus.
Eur Urol
. 2014 Sep; 66(3): 577–83.
26.
Harada K, Miyake H, Kusuda Y, Fujisawa M. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in -patients undergoing radical nephrectomy. 
BJU Int
. 2012 Dec; 110(11c 11 Pt C):E1131–7.
27.
Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, et al. Expression of Snail and Slug in renal cell carcinoma: e-cadherin repressor Snail is associated with cancer invasion and prognosis.
Lab Invest
. 2011 Oct; 91(10): 1443–58.
28.
Bilim V, Kawasaki T, Katagiri A, Wakatsuki S, Takahashi K, Tomita Y. Altered expression of beta-catenin in renal cell cancer and transitional cell cancer with the absence of beta-catenin gene mutations.
Clin Cancer Res
. 2000 Feb; 6(2): 460–6.
29.
López JI, Mosteiro L, Guarch R, Larrinaga G, Pulido R, Angulo JC. Low-grade metastases in high-grade clear cell renal cell carcinomas: A clinicopathologic study of 4 cases with an insight into the role of mesenchymal-to-epithelial transition process.
Ann Diagn Pathol
. 2016 Feb; 20: 13–8.
30.
Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma.
Cancer Biol Ther
. 2010 Oct; 10(7): 658–64.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.